Pacific Biosciences of California, Inc. (NASDAQ:PACB) will issue its quarterly earnings data after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). Pacific Biosciences of California had a negative return on equity of 93.31% and a negative net margin of 89.67%. The business had revenue of $20.07 million for the quarter, compared to analyst estimates of $23.34 million. During the same period last year, the business earned ($0.21) EPS. Pacific Biosciences of California’s revenue was down 3.2% compared to the same quarter last year. On average, analysts expect Pacific Biosciences of California to post $-0.89 EPS for the current fiscal year and $-0.64 EPS for the next fiscal year.

Shares of Pacific Biosciences of California, Inc. (NASDAQ PACB) opened at 4.29 on Tuesday. Pacific Biosciences of California, Inc. has a 52 week low of $3.08 and a 52 week high of $8.94. The firm’s market capitalization is $495.89 million. The stock has a 50 day moving average price of $5.02 and a 200-day moving average price of $4.20.

PACB has been the subject of a number of research analyst reports. CL King downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price objective for the company. in a report on Thursday, September 28th. BidaskClub downgraded Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research downgraded Pacific Biosciences of California from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $8.93.

ILLEGAL ACTIVITY WARNING: “Pacific Biosciences of California, Inc. (PACB) Set to Announce Quarterly Earnings on Tuesday” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/24/pacific-biosciences-of-california-inc-pacb-set-to-announce-quarterly-earnings-on-tuesday.html.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Earnings History for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com's FREE daily email newsletter.